Responders and partial responders to tolterodine extended release: Effect of fesoterodine in tolterodine partial responders

Trial Profile

Responders and partial responders to tolterodine extended release: Effect of fesoterodine in tolterodine partial responders

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 May 2014

At a glance

  • Drugs Fesoterodine (Primary)
  • Indications Overactive bladder; Urinary incontinence
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 19 May 2014 New trial record
    • 15 Apr 2014 Results presented at the 29th Congress of the European Association of Urology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top